Key result
CHIP mutations at myeloid neoplasm diagnosis show no association with incident cardiovascular events.
Why the study?
Does the presence of CHIP-associated gene mutations at myeloid neoplasm diagnosis predict incident cardiovascular and cerebrovascular events in adults?
Cohort (n=203)
No
Does the presence of CHIP-associated gene mutations at myeloid neoplasm diagnosis predict incident cardiovascular and cerebrovascular events in adults?
p-value: p=0.29
Unlike in the general population, CHIP-associated gene mutations at the time of myeloid neoplasm diagnosis do not independently predict incident cardiovascular or cerebrovascular events, though they are linked to higher all-cause mortality.
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP)-associated somatic mutations are associated with increased cardiovascular and cerebrovascular risk in the general population; whether mutations detected at myeloid neoplasm (MN) diagnosis predict incident cardiovascular and cerebrovascular events (CCVEs) is unclear. METHODS: We retrospectively studied 203 adults with newly diagnosed myelodysplastic neoplasms, myelodysplastic/myeloproliferative neoplasms, or acute myeloid leukemia unfit for intensive chemotherapy (2016-2023) who underwent pretreatment next-generation sequencing. Cause-specific hazard models adjusted for cardiovascular risk factors assessed associations between CHIP-associated gene mutations and incident CCVEs, including age-stratified and age-by-mutation interaction analyses. RESULTS: =0.29). In multivariable models, CHIP-associated gene mutations, higher-risk MN, and incident CCVEs were each associated with higher all-cause mortality. CONCLUSIONS: CHIP-associated gene mutations at MN diagnosis were not independently associated with incident CCVEs. Older mutation-positive patients had higher observed CCVE risk, predominantly heart failure, with limited precision. These exploratory findings warrant prospective multicenter validation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Myeloid neoplasms (myelodysplastic neoplasms, myelodysplastic/myeloproliferative neoplasms, or acute myeloid leukemia) (n=203). CHIP-associated gene mutations vs. Absence of CHIP-associated gene mutations was evaluated on Incident cardiovascular and cerebrovascular events (CCVEs) (p=0.29). CHIP-associated gene mutations at myeloid neoplasm diagnosis were not independently associated with incident cardiovascular and cerebrovascular events (P=0.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: